Plus: federal regulators close investigation into Tesla’s autonomous summon feature. And Neurocrine Biosciences agrees to acquire Soleno Therapeutics for $2.9 billion. Danny Lewis hosts.
Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.